Market Overview

Vetr Thinks Regeneron Is Looking Healthy


On Friday, the Vetr crowd upgraded their rating of Regeneron Pharmaceuticals Inc (NASDAQ: REGN) from 4 stars (buy), issued two days ago, to 4.5 stars (strong buy). Expectation for the stock is high with 83 percent of user ratings bullish.

After hitting a peak of $444.52 last week, Regeneron shares closed last week out a little lower at $397.48. This following a sizeable drop in healthcare stock at the start of Tuesday’s session, which saw a 5 percent fall and a 7 percent drop for Valeant Pharmaceuticals Intl Inc (NYSE: VRX).

See how crowdsourced ratings could help you time the market.

The Vetr crowd has Regeneron’s average target price at $461.47, which is below the average analyst price of $471.38. Less than 2 percent of Vetr users are holding REGN in their watch lists.

Posted-In: VetrFintech Sector ETFs Upgrades Crowdsourcing Analyst Ratings ETFs General


Related Articles (REGN + VRX)

View Comments and Join the Discussion!

Foot Locker's Diversified Business Model Makes It A Buy

The Vetr Crowd Isn't Banking On Wells Fargo